FITC-Labeled Human BAFF, Fc Tag (Cat. No. BAF-HF268) is expressed from human HEK293 cells. It contains AA Ala 134 - Leu 285 (Accession # AAH20674.1). It is the FITC labeled form of Human BAFF, Fc Tag (Cat. No. BAF-H4268).
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular seive treatment during purification process.
The FITC to protein molar ratio is 1.5-3.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
4-8°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
FITC-Labeled Human BAFF, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human BCMA, Fc Tag (Cat. No. BC7-H5254) at 10 μg/mL (100 μL/well) can bind FITC-Labeled Human BAFF, Fc Tag (Cat. No. BAF-HF268) with a linear range of 0.156-2.5 μg/mL (Ex.488 nm/Em.535 nm) (QC tested).
B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells.